Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2023 · 10-Q
Revenue$9.66M$9.66M+21.9% vs Q1 2022 Net Income$514.00K$514.00KN/M vs Q1 2022 EPS Diluted$0.12$0.12N/M vs Q1 2022 Gross Profit$6,141,000+31.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow$1,133,000N/M Free Cash Flowderived$1,068,000N/M Margins · derivedGross margin63.6%+4.8 pt vs Q1 2022
Operating margin8.7%+21.0 pt vs Q1 2022
Net margin5.3%+33.7 pt vs Q1 2022
ended Mar 31, 2023 · filed May 12, 2023 · 42 d after period end